Selected article for: "adolescent patient and lmwh molecular weight heparin"

Author: Desdiani, Desdiani; Yulianti, Nita; Basuki, Anindita
Title: Delayed hypercoagulable state in COVID‐19 adolescent patient: a case report
  • Cord-id: tg8664iq
  • Document date: 2021_6_8
  • ID: tg8664iq
    Snippet: Coronavirus disease 2019 (COVID‐19) is a systemic hyperinflammation disease which can cause severe respiratory symptoms and extrapulmonary manifestations. Hypercoagulable state in COVID‐19 adolescent patient is a rare case. We present the case of a 16‐year‐old Indonesian boy with mild COVID‐19 symptoms. Initially, the patient was treated with azithromycin, N‐acetyl cysteine, etc. After several days of the treatment, there was clinical improvement. However, on day 15, the patient expe
    Document: Coronavirus disease 2019 (COVID‐19) is a systemic hyperinflammation disease which can cause severe respiratory symptoms and extrapulmonary manifestations. Hypercoagulable state in COVID‐19 adolescent patient is a rare case. We present the case of a 16‐year‐old Indonesian boy with mild COVID‐19 symptoms. Initially, the patient was treated with azithromycin, N‐acetyl cysteine, etc. After several days of the treatment, there was clinical improvement. However, on day 15, the patient experienced hypercoagulation and stroke‐like symptoms. The patient was then subjected to additional drugs, including low‐molecular weight heparin (LMWH), and peripheral neuropathy vitamin therapy. On day 20, the clinical symptoms reduced. This case demonstrates the need for further study of the association between COVID‐19 and stroke in young population and the use of anticoagulants to prevent thrombotic events.

    Search related documents:
    Co phrase search for related documents